ANIP ANI Pharmaceuticals, Inc.
$71.17▼ -1.97%
Healthcare
Other
After hours
$71.17▲ +0.00%
Oct 27, 4:02 PM ET
Volume 285.2K
Avg Volume (10D) 304.2K
Key Metrics & Fundamentals
Market Cap
$1.63B
P/E Ratio
15.4
Div Yield
0.00%
52W Range
69.58 - 95.57
% vs 50 MA
-2.85%
% vs 200 MA
-8.55%
RSI-14
43.2
MACD Histogram
+0.0500
Beta (1Y vs SPY)
0.25
Free Cash Flow
$53.62M
Gross Rev
$266.04M
Gross Profit
$165.89M
EBITDA
$59.01M
COGS
$100.16M
Operating Exp
$126.05M
Operating Income
$39.84M
EBIT
$39.84M
Pretax Income
$37.10M
Net Income
$24.71M
EPS (Diluted)
1.05
Price & Volume History
Loading chart…
Recent News
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
GlobeNewswire · Oct 23, 2026 6:55 AM ET
ANI Pharmaceuticals' Eye-Care Franchise Faces New Competition, Oppenheimer Says
MT Newswires · Oct 22, 2026 12:15 PM ET
ANI Pharmaceuticals Launches Generic Cymbalta
MT Newswires · Oct 19, 2026 7:32 AM ET
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
GlobeNewswire · Oct 19, 2026 6:55 AM ET
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
Zacks · Oct 13, 2026 11:10 AM ET
ANI Pharmaceuticals Says Phase 4 Trial of Iluvien Meets Endpoints in Chronic NIU-PS
MT Newswires · Oct 12, 2026 7:44 AM ET
ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting
GlobeNewswire · Oct 12, 2026 6:55 AM ET
Did FDA Approval of Generic Everolimus Suspension Just Shift ANI Pharmaceuticals' (ANIP) Investment Narrative?
Simply Wall St. · Oct 7, 2026 6:13 PM ET
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Turn Down
StockStory · Oct 6, 2026 5:44 AM ET
1 Small-Cap Stock for Long-Term Investors and 2 We Ignore
StockStory · Oct 1, 2026 8:13 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ANIP's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.